Levels of IL-6, TNFα, and IL-17 were slightly decreased in the pancreas of C-MSC-treated and T1D-MSC-treated responder mice compared with the control group; however, these differences were not significant (P >0.05; Fig. 7). Here, IL17A is linked to type 1 diabetes mellitus.